It has been just revealed the fact that Pfizer chose to lose 1.38 billion customers rather than check its products’ safety. Here are the latest reports about this below.
Pfizer chooses to lose customers rather than check product safety
Check out this relevant tweet below:
Indian authorities to Pfizer: “You can either lose 1.38 billion customers or allow an independent investigation to be conducted to determine if your products are safe and provides immunity.”
Pfizer chose to give up the 1.38 billion customers.
Let that sink in. pic.twitter.com/5byBCJDarb
— •Ɛɱɱყ• (@brixwe) July 20, 2023
Someone noted the fact that “India is the biggest manufacturer of vaccines, Pfizer had declined to share its technology and historically India prefers that everything is made in collaboration with local industries.”
The Serum Institute of India, founded in 1966 in Pune, India, produces immunobiologicals that were previously imported at high prices.
With a focus on manufacturing tetanus antitoxin, snake antivenom, DPT vaccine, and MMR vaccine, the company has expanded its product line to include vaccines for bacterial or viral infections, combination vaccines, influenza vaccine, and meningococcal vaccine.
Additionally, they manufacture antisera, blood plasma, and hormone products. The vaccines produced by the Serum Institute of India have been utilized in international vaccination programs by the World Health Organization (WHO), UNICEF, and the Pan American Health Organization (PAHO) since 2014. Today, the Poonawalla Group runs the Serum Institute of India and oversees their research, development, and manufacturing.
A person noted on Twitter something that’s completely true. The biggest scam is that you can’t sue Pfizer or Moderna if you have severe Covid vaccine side effects. The government won’t compensate you for damages either and the corrupt FDA cannot be sued either. Big Pharma easily manipulates the press & social media companies while simultaneously infusing billions of dollars into political campaigns.
Stay tuned for more news about the issue.